Novartis has signed a second molecular-glue partnership with Orionis Biosciences, adding $40 million upfront and up to $1.4 billion in milestone-based consideration. The deal focuses on Orionis’s ability to address challenging therapeutic targets across multiple disease areas. The collaboration builds on an earlier agreement between Novartis and Orionis, signaling continued internal confidence in the molecular-glue platform approach. For Orionis, the structure provides near-term funding while tying additional payments to clinical and development milestones. For the broader biotech market, the second deal reinforces Big Pharma’s willingness to re-up on platform bets when early target-validation work looks promising enough to sustain a pipeline commitment.